Table 2 Disaggregated costs and outcomes of ofatumumab compared to best supportive care
Best supportive care | Ofatumumab | Incremental | |
|---|---|---|---|
Costs | |||
Drug costs | £0 | £35,081 | £35,081 |
Administration costs | £0 | £1834 | £1834 |
Adverse event costs | £1665 | £1339 | −£326 |
Pre-progression healthcare costs | £2183 | £3782 | £1600 |
Post-progression healthcare costs | £908 | £1906 | £998 |
Total cost | £4756 | £43,942 | £39,186 |
Life years | |||
Progression-free life years | 0.379 | 0.543 | 0.163 |
Post-progression life years | 0.498 | 0.952 | 0.453 |
Total life years | 0.877 | 1.494 | 0.617 |
Quality-adjusted life years (QALYs) | |||
Progression-free QALYs | 0.244 | 0.348 | 0.104 |
Post-progression QALYs | 0.225 | 0.421 | 0.196 |
Total QALYs | 0.469 | 0.770 | 0.301 |
Cost-effectiveness ratios | |||
Cost per life year | £63,542 | ||
Cost per QALY | £130,563 | ||